The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia

• Status: Terminated
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to find out if the combined therapy lumacaftor-ivacaftor affects glycemia in patient with cystic fibrosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Ivacaftor

Criteria

Inclusion Criteria:

1. Age 18 years old or greater

2. Patients diagnosed with cystic fibrosis (CF), genotype homozygous Phe508del

3. Subject has been started on lumacaftor-ivacaftor for clinical reasons, with no contraindication for starting the drug* * Contraindications for taking drug include abnormal liver enzyme tests, renal dysfunction, pregnancy or nursing mothers

Exclusion Criteria

1. Does not have a HgbA1c within 1 year prior to starting medication.

2. Has not been on the combination therapy for at least 2 months